Multiple-parameter MRI After Neoadjuvant Systemic Therapy Combining Clinicopathologic Features in Evaluating Axillary Pathologic Complete Response in Patients with Clinically Node-positive Breast Cancer

Overview

Journal Br J Radiol

Publisher Oxford University Press

Specialty Radiology

Date 2022 Aug 24

PMID 36000676

Authors

Minglei Chen

Zeyan Xu

Chao Zhu

Yulin Liu

Yunrui Ye

Chen Liu

Zaiyi Liu

Changhong Liang

Chunling Liu

Affiliations

Soon will be listed here.

Abstract

Objective: This study aimed to evaluate axillary pathologic complete response (pCR) after neoadjuvant systemic therapy (NST) in clinically node-positive breast cancer (BC) patients based on post-NST multiple-parameter MRI and clinicopathological characteristics.

Methods: In this retrospective study, females with clinically node-positive BC who received NST and followed by surgery between January 2017 and September 2021 were included. All axillary lymph nodes (ALNs) on MRI were matched with pathology by ALN markers or sizes. MRI morphological parameters, signal intensity curve (TIC) patterns and apparent diffusion coefficient (ADC) values of post-NST ALNs were measured. The clinicopathological characteristics was also collected and analyzed. Univariable and multivariable logistic regression analyses were performed to evaluate the independent predictors of axillary pCR.

Results: Pathologically confirmed 137 non-pCR ALNs in 71 patients and 87 pCR ALNs in 87 patients were included in this study. Cortical thickness, fatty hilum, and TIC patterns of ALNs, hormone receptor, and human epidermal growth factor receptor 2 (HER2) status were significantly different between the two groups (all, < 0.05). There was no significant difference for ADC values ( = 0.875). On multivariable analysis, TIC patterns (odds ratio [OR], 2.67, 95% confidence interval [CI]: 1.33, 5.34, = 0.006), fatty hilum (OR, 2.88, 95% CI:1.39, 5.98, = 0.004), hormone receptor (OR, 8.40, 95% CI: 2.48, 28.38, = 0.001) and HER2 status (OR, 8.57, 95% CI: 3.85, 19.08, < 0.001) were identified as independent predictors associated with axillary pCR. The area under the curve of the multivariate analysis using these predictors was 0.85 (95% CI: 0.79, 0.91).

Conclusion: Combining post-NST multiple-parameter MRI and clinicopathological characteristics allowed more accurate identification of BC patients who had received axillary pCR after NST.

Advances In Knowledge: A combined model incorporated multiple-parameter MRI and clinicopathologic features demonstrated good performance in evaluating axillary pCR preoperatively and non-invasively.

Citing Articles

Delta dual‑region DCE-MRI radiomics from breast masses predicts axillary lymph node response after neoadjuvant therapy for breast cancer.

Zeng Q, Deng Y, Nan J, Zou Z, Yu T, Liu L BMC Cancer. 2025; 25(1):264.

PMID: 39953506 PMC: 11827315. DOI: 10.1186/s12885-025-13678-z.

Machine learning approaches in the prediction of positive axillary lymph nodes post neoadjuvant chemotherapy using MRI, CT, or ultrasound: A systematic review.

Yaghoobpoor S, Fathi M, Ghorani H, Valizadeh P, Jannatdoust P, Tavasol A Eur J Radiol Open. 2024; 12:100561.

PMID: 38699592 PMC: 11063585. DOI: 10.1016/j.ejro.2024.100561.

Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1-3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study.

Bae S, Chun J, Lee S, Ryu J, Nam S, Jeong J Breast Cancer Res. 2024; 26(1):66.

PMID: 38632652 PMC: 11022328. DOI: 10.1186/s13058-024-01807-8.

References

He N, Xie C, Wei W, Pan C, Wang W, Lv N . A new, preoperative, MRI-based scoring system for diagnosing malignant axillary lymph nodes in women evaluated for breast cancer. Eur J Radiol. 2012; 81(10):2602-12. DOI: 10.1016/j.ejrad.2012.03.019. View

Wang H, Li J, Chen F, De Keyzer F, Yu J, Feng Y . Morphological, functional and metabolic imaging biomarkers: assessment of vascular-disrupting effect on rodent liver tumours. Eur Radiol. 2010; 20(8):2013-26. DOI: 10.1007/s00330-010-1743-5. View

Heil J, Kuerer H, Pfob A, Rauch G, Sinn H, Golatta M . Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. Ann Oncol. 2020; 31(1):61-71. DOI: 10.1016/j.annonc.2019.10.012. View

Kim W, Kim H, Lee S, Cho S, Shin K, Lee S . Preoperative axillary nodal staging with ultrasound and magnetic resonance imaging: predictive values of quantitative and semantic features. Br J Radiol. 2018; 91(1092):20180507. PMC: 6319840. DOI: 10.1259/bjr.20180507. View

Ramirez-Galvan Y, Cardona-Huerta S, Elizondo-Riojas G, Alvarez-Villalobos N, Campos-Coy M, Ferrara-Chapa C . Does axillary lymph node size predict better metastatic involvement than apparent diffusion coefficient (ADC) value in women with newly diagnosed breast cancer?. Acta Radiol. 2020; 61(11):1494-1504. DOI: 10.1177/0284185120903449. View

Luciani A, Pigneur F, Ghozali F, Dao T, Cunin P, Meyblum E . Ex vivo MRI of axillary lymph nodes in breast cancer. Eur J Radiol. 2008; 69(1):59-66. DOI: 10.1016/j.ejrad.2008.07.040. View

Wang L, Li Y, Li J, Wang T, Xie Y, He Y . Computed tomography reconstruction for evaluating response in axillary lymph nodes of breast cancer after neoadjuvant chemotherapy. Clin Transl Oncol. 2020; 23(2):240-245. DOI: 10.1007/s12094-020-02411-w. View

Ha R, Chang P, Karcich J, Mutasa S, Pascual Van Sant E, Connolly E . Predicting Post Neoadjuvant Axillary Response Using a Novel Convolutional Neural Network Algorithm. Ann Surg Oncol. 2018; 25(10):3037-3043. DOI: 10.1245/s10434-018-6613-4. View

Boughey J, Ballman K, Le-Petross H, McCall L, Mittendorf E, Ahrendt G . Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071.... Ann Surg. 2015; 263(4):802-7. PMC: 4777661. DOI: 10.1097/SLA.0000000000001375. View

10.

Sclafani L, Baron R . Sentinel lymph node biopsy and axillary dissection: added morbidity of the arm, shoulder and chest wall after mastectomy and reconstruction. Cancer J. 2008; 14(4):216-22. DOI: 10.1097/PPO.0b013e31817fbe5e. View

11.

Kvistad K, Rydland J, Smethurst H, Lundgren S, Fjosne H, Haraldseth O . Axillary lymph node metastases in breast cancer: preoperative detection with dynamic contrast-enhanced MRI. Eur Radiol. 2000; 10(9):1464-71. DOI: 10.1007/s003300000370. View

12.

Myers S, Ahrendt G, Lee J, Steiman J, Soran A, Johnson R . Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg Oncol. 2021; 28(13):8636-8642. DOI: 10.1245/s10434-021-10195-8. View

13.

Arslan G, Murzoglu Altintoprak K, Kizildag Yirgin I, Atasoy M, Celik L . Diagnostic accuracy of metastatic axillary lymph nodes in breast MRI. Springerplus. 2016; 5(1):735. PMC: 4909659. DOI: 10.1186/s40064-016-2419-7. View

14.

Scaranelo A, Eiada R, Jacks L, Kulkarni S, Crystal P . Accuracy of unenhanced MR imaging in the detection of axillary lymph node metastasis: study of reproducibility and reliability. Radiology. 2011; 262(2):425-34. DOI: 10.1148/radiol.11110639. View

15.

Belli P, Bufi E, Buccheri C, Rinaldi P, Giuliani M, Romani M . Role of DWI assessing nodal involvement and response to neoadjuvant chemotherapy in advanced breast cancer. Eur Rev Med Pharmacol Sci. 2017; 21(4):695-705. View

16.

Kamitani T, Hatakenaka M, Yabuuchi H, Matsuo Y, Fujita N, Jinnouchi M . Detection of axillary node metastasis using diffusion-weighted MRI in breast cancer. Clin Imaging. 2012; 37(1):56-61. DOI: 10.1016/j.clinimag.2012.02.014. View

17.

Hennessy B, Hortobagyi G, Rouzier R, Kuerer H, Sneige N, Buzdar A . Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005; 23(36):9304-11. DOI: 10.1200/JCO.2005.02.5023. View

18.

Mansel R, Fallowfield L, Kissin M, Goyal A, Newcombe R, Dixon J . Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006; 98(9):599-609. DOI: 10.1093/jnci/djj158. View

19.

Mann R, Cho N, Moy L . Breast MRI: State of the Art. Radiology. 2019; 292(3):520-536. DOI: 10.1148/radiol.2019182947. View

20.

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View